Literature DB >> 28228838

A Rare Case of Bilateral Optic Neuritis and Guillain-Barré Syndrome Post Mycoplasma pneumoniae Infection.

Aravindhan Baheerathan1, Amy Ross Russell1, Fion Bremner2, Simon F Farmer1.   

Abstract

Neurological complications are the most commonly encountered extra-pulmonary manifestation of infection with Mycoplasma pneumoniae (M. pneumoniae). Here the authors report the case of a 39-year-old woman who was admitted with acute-onset bilateral visual loss coinciding with ascending numbness. Clinical examination, neurological imaging, and nerve conduction studies revealed a syndrome of bilateral optic neuritis and Guillain-Barré syndrome (GBS). Serological testing confirmed recent exposure to M. pneumoniae. The patient did not experience any clinical benefit with pulsed intravenous methylprednisolone but demonstrated marked clinical and radiological improvement following 5 days of plasma exchange. This report will explore the diagnostic and therapeutic approach to patients with neuro-ophthalmological and neurological complications of M. pneumoniae infection in addition to discussing previously encountered cases.

Entities:  

Keywords:  Guillain-Barré syndrome; Mycoplasma pneumoniae; optic neuritis; plasma exchange; post-infectious inflammatory neuropathy; post-infectious optic neuropathy

Year:  2016        PMID: 28228838      PMCID: PMC5278787          DOI: 10.1080/01658107.2016.1237975

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  18 in total

1.  Bilateral optic neuritis and Guillain-Barré syndrome following an acute Mycoplasma pneumoniae infection.

Authors:  Ricardo C Ginestal; José F Plaza; Juán Manuel Callejo; Norberto Rodríguez-Espinosa; Luis Carlos Fernández-Ruiz; Jaime Masjuán
Journal:  J Neurol       Date:  2004-06       Impact factor: 4.849

2.  Central nervous system disease complicating Mycoplasma pneumoniae.

Authors:  Tomoko Watanabe; Kotaro Hatta; Tsuneyoshi Ota; Yasushi Shimo; Heii Arai
Journal:  Psychiatry Clin Neurosci       Date:  2007-10       Impact factor: 5.188

3.  Combined Striatum, Brain Stem, and Optic Nerve Involvement due to Mycoplasma pneumoniae in an Ambulatory Child.

Authors:  Jin-Won Bae; Hak-Jin Kim; Gregory Youngnam Chang; Eun-Joo Kim
Journal:  Case Rep Neurol       Date:  2011-05-13

Review 4.  Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia.

Authors:  Mitsuo Narita
Journal:  J Infect Chemother       Date:  2010-02-27       Impact factor: 2.211

5.  Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature.

Authors:  B Pfausler; K Engelhardt; A Kampfl; H Spiss; E Taferner; E Schmutzhard
Journal:  Eur J Neurol       Date:  2002-01       Impact factor: 6.089

6.  Meningoencephalitis-like onset of post-infectious AQP4-IgG-positive optic neuritis complicated by GM1-IgG-positive acute polyneuropathy.

Authors:  Luana Benedetti; Diego Franciotta; Alessandro Beronio; Stefano Delucchi; Cesare Capellini; Massimo Del Sette
Journal:  Mult Scler       Date:  2014-02-20       Impact factor: 6.312

7.  Guillain-Barré syndrome (GBS) with bilateral optic neuritis and central white matter disease.

Authors:  N Nadkarni; R P Lisak
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

8.  Optic neuritis as a presenting symptom of Mycoplasma pneumoniae infection.

Authors:  Yasemin Özkale; İlknur Erol; Müge Çoban-Karataş; Özlem Alkan
Journal:  Turk J Pediatr       Date:  2015 Jul-Aug       Impact factor: 0.552

9.  Reversible neurological syndromes with atypical pneumonia.

Authors:  Ashok Panagariya; A K Sharma; Amit Dev; Arvind Kankane; Bhawna Sharma; Parul Dubey
Journal:  Ann Indian Acad Neurol       Date:  2011-04       Impact factor: 1.383

10.  Mycoplasma pneumoniae infection with neurologic complications.

Authors:  Sevgi Yimenicioğlu; Ayten Yakut; Arzu Ekici; Kursat Bora Carman; Ener Cagrı Dinleyici
Journal:  Iran J Pediatr       Date:  2014-07-27       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.